Mallinckrodt to distribute Myoview
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of restricted blood supply to the heart muscle, according to the company.
Mallinckrodt of St. Louis and Medi-Physics of Arlington Heights, IL, will both provide the agent in the U.S. The agreement also includes a five-year extension.
In other Mallinckrodt news, the company has jointly announced with Molecular Biosystems that MBI's FS069 second-generation ultrasound contrast agent has been given the brand name Optison. Regulatory activity by the Food and Drug Administration on that agent has been temporarily halted following a U.S. District Court preliminary injunction on April 21 (SCAN 4/30/97).
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
